伽玛刀放射外科治疗术后无功能性垂体腺瘤的长期随访研究
本研究纳入2000年1月至2010年12月间204例术后残留或复发无功能性垂体腺瘤患者,接受伽玛刀放射外科治疗。中位随访86个月,肿瘤控制率为90%,3、5、8、10、15年累积无进展生存率分别为97%、95%、92%、92%、81%。37例(18%)出现新发垂体功能减退。作者推荐对次全切除术后约6个月的残留无功能性垂体腺瘤考虑早期伽玛刀放射外科作为常规辅助治疗。
要点
- 204例术后残留或复发无功能性垂体腺瘤患者接受伽玛刀放射外科,中位随访86个月。
- 肿瘤控制率90%,15年累积无进展生存率81%。
- 37例(18%)出现新发垂体功能减退,无新发颅神经功能障碍或第二脑肿瘤。
核心结论
- 伽玛刀放射外科在长期随访中提供高肿瘤控制率和低并发症率。
- 作者推荐对次全切除术后约6个月的残留无功能性垂体腺瘤考虑早期伽玛刀放射外科作为常规辅助治疗。
研究设计与样本
- 研究纳入2000年1月至2010年12月间204例术后残留或复发无功能性垂体腺瘤患者,接受伽玛刀放射外科治疗。
- 患者中位年龄48岁(平均48岁,范围14-79岁),中位肿瘤体积3.3 mL(平均5.2 mL,范围0.3-26.4 mL)。
- 中位边缘剂量14 Gy(平均14 Gy,范围9-18 Gy),中位最大剂量31 Gy(平均30 Gy,范围20-40 Gy)。
- 中位随访时间86个月(平均88个月,范围12-213个月)。
主要发现
- 末次随访MRI显示肿瘤缩小102例(50%),肿瘤稳定81例(40%),肿瘤增大21例(10%)。
- 本队列肿瘤控制率为90%。
- 3、5、8、10、15年累积无进展生存率分别为97%、95%、92%、92%、81%。
- 37例(18%)出现新发垂体功能减退,其中1例全垂体功能减退。
- 5例(2.5%)出现新发或加重视觉功能障碍而无肿瘤生长,未发现新发颅神经功能障碍和第二脑肿瘤。
临床怎么用
- 作者推荐对次全切除术后约6个月的残留无功能性垂体腺瘤考虑早期伽玛刀放射外科作为常规辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the long-term clinical outcomes of Gamma Knife radiosurgery (GKRS) for residual and recurrent nonfunctioning pituitary adenomas (NFPAs) after surgery and the role of GKRS in the management of NFPAs. METHODS: Between January 2000 and December 2010, 204 patients with residual or recurrent NFPAs undergoing GKRS were enrolled in this study according to the inclusion criteria. The median age of the patients was 48 years (mean, 48 years; range, 14-79 years). The median tumor volume was 3.3 mL (mean, 5.2 mL; range, 0.3-26.4 mL). The median margin dose was 14 Gy (mean, 14 Gy; range, 9-18 Gy). The median maximum dose was 31 Gy (mean, 30 Gy; 20-40 Gy). The median duration of follow-up was 86 months (mean, 88 months; range, 12-213 months). RESULTS: Of these 204 patients, the latest follow-up magnetic resonance imaging studies showed tumor regression in 102 patients (50%), tumor stability in 81 patients (40%), and tumor enlargement in 21 patients (10%). The tumor control rate of this cohort was 90%. The cumulative progression-free survival at 3, 5, 8, 10, and 15 years was 97%, 95%, 92%, 92%, and 81%, respectively. Thirty-seven patients (18%) developed new-onset hypopituitarism, with 1 patient experiencing panhypopituitarism. Five patients (2.5%) presented with new or worsening visual dysfunction without tumor growth. No new cranial nerve dysfunction was shown and no second brain tumor was identified. CONCLUSIONS: GKRS provided high tumor control and a low complication rate in our long-term follow-up. We recommend that early GKRS should be considered the routine adjuvant treatment for residual NFPAs approximately 6 months after subtotal surgical resection.
引用
- Sun S, Liu A, Zhang Y, et al. Long-Term Follow-Up Studies of Gamma Knife Radiosurgery for Postsurgical Nonfunctioning Pituitary Adenomas. World Neurosurg. 2019. PMID: 30660894. doi:10.1016/j.wneu.2019.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。